Drug intelligence / Profile preview

UX-SP001

Development stage: Preclinical
Lead developer: UniXell Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

UX-SP001 is a preclinical-stage cell therapy being developed by Shanghai UniXell Biotechnology for the treatment of spinal cord injury. The therapy consists of human induced pluripotent stem cell (hiPSC)-derived spinal cord neural progenitor cells. The mechanism of action involves the transplantation of these progenitor cells into the site of injury to promote neural repair, replace damaged or lost neurons and glial cells, and support functional recovery. Shanghai UniXell utilizes its proprietary technology platforms, including reprogramming, stem cell differentiation, and SISBAR lineage tracing, to develop these specialized neural products.

Other names: hiPSC-derived spinal cord neural progenitor cells

Beyond the preview

Go deeper on UX-SP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UX-SP001.

Explore the full profile